Pineoblastoma
Learn about Pineoblastoma, its reported features, relevant specialists, and questions to discuss at a medical consultation.
The sources compiled here do not cover: diagnosis, treatment, prevention. Ask the treating doctor about these.
What it is
From: Orphanet
Pineoblastoma is a rare, malignant type of supratentorial primitive neuroectodermal tumor (sPNET), found mainly in children (less than 10% of cases are reported in adults), and located in the pineal region of the brain but that can metastasize along the neuroaxis. As it is the most aggressive of the pineal parenchymal tumors, it is usually associated with a poor prognosis.
Reported clinical features and what the terms mean
The following findings are associated with this condition in Orphanet. They are not a checklist for diagnosing yourself, and they do not all occur in every affected person. Some are examination, imaging or laboratory findings that cannot be recognised at home.
The frequency labels describe how often a finding was reported among people with the condition in the source. They do not give the chance that a person with that symptom has the condition. Definitions below reproduce HPO terminology; they explain the term, not the likely severity in an individual.
- Headache · Very frequent (99-80%)
- Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve.
- Pinealoma · Obligate (100%)
- A neoplasm of the pineal gland.
- Atypical behavior · Frequent (79-30%)
- Atypical behavior is an abnormality in a person's actions that can be controlled or modulated by the will of the individual. While abnormal behaviors can be difficult to control, they are distinct from other abnormal actions that cannot be affected by the individual's will.
- Cognitive impairment · Frequent (79-30%)
- Abnormal cognition is characterized by deficits in thinking, reasoning, or remembering.
- Increased intracranial pressure · Frequent (79-30%)
- An increase of the pressure inside the cranium (skull) and thereby in the brain tissue and cerebrospinal fluid.
- Memory impairment · Frequent (79-30%)
- An impairment of memory as manifested by a reduced ability to remember things such as dates and names, and increased forgetfulness.
- Progressive neurologic deterioration · Frequent (79-30%)
- Amaurosis fugax · Occasional (29-5%)
- A transient visual disturbance that is typically caused by a circulatory, ocular or neurological underlying condition.
- Impaired convergence · Occasional (29-5%)
- Reduced ability to turn the eyes inward in order to focus on a nearby object.
- Papilledema · Occasional (29-5%)
- Papilledema refers to edema (swelling) of the optic disc secondary to any factor which increases cerebral spinal fluid pressure.
- Paralysis · Occasional (29-5%)
- Paralysis of voluntary muscles means loss of contraction due to interruption of one or more motor pathways from the brain to the muscle fibers. Although the word paralysis is often used interchangeably to mean either complete or partial loss of muscle strength, it is preferable to use paralysis or plegia for complete or severe loss of muscle strength, and paresis for partial or slight loss. Motor paralysis results from deficits of the upper motor neurons (corticospinal, corticobulbar, or subcorticospinal). Motor paralysis is often accompanied by an impairment in the facility of movement.
- Retinoblastoma · Occasional (29-5%)
- A tumor of the eye originating from cells of the retina.
- Seizure · Occasional (29-5%)
- A seizure is an intermittent abnormality of nervous system physiology characterized by a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain.
- Sensory neuropathy · Occasional (29-5%)
- Peripheral neuropathy affecting the sensory nerves.
Other findings in the same source
From: Orphanet
Additional reported features include Midline brain calcifications (Occasional (29-5%)); Progressive visual field defects (Occasional (29-5%)); Reduced visual acuity (Occasional (29-5%)); Lethargy (Very rare (<4-1%)); Reduced consciousness (Very rare (<4-1%)). This is a selected summary, not a complete description of the condition.
When it may begin
From: Orphanet
Adolescent; Adult; Childhood; Infancy
Inheritance in the source
From: Orphanet
Not applicable
Frequency and the population described
From: Orphanet
Annual incidence: <1 / 1 000 000; Europe; Value and class.
Which doctor should you see?
The suggested department for discussing Pineoblastoma is Oncology, with a oncologist and relevant organ specialist as the relevant type of clinician. General physician / Family Medicine; paediatrician for children. Referral depends on symptoms.
Additional services that may be relevant, depending on the findings, include: Relevant organ specialist / Surgical Oncology as indicated.
This is an editorial referral starting point. The appropriate clinic depends on the person’s age, symptoms, previous diagnosis and local services. The first clinician can decide whether another specialty or a team is needed; a department label does not confirm the diagnosis.
How to prepare for an assessment
Bring a short timeline of the main symptoms: when they first appeared, whether they are constant or episodic, what seems to change them, and how they affect daily activities. Include previous reports, discharge summaries, current medicines and supplements, allergies, and any relevant family history. A dated record is more useful than trying to match every feature in an online article.
Ask the clinician what is already established and what remains uncertain. If a test is suggested, ask what question it answers, what its limitations are and how the result would change the next step. The information here is not an instruction to arrange every possible test. In children, bring growth, developmental and school information if it is relevant to the concern.
- Has the exact tumour type been confirmed, and is staging relevant?
- What is the goal of each proposed treatment option?
- How will side effects, daily function and supportive care be addressed?
Treatment discussions and follow-up
The material gathered for this draft does not provide a complete condition-specific treatment pathway for Pineoblastoma. That gap does not mean that treatment is unavailable. A clinician needs to establish the diagnosis and review current guidance before recommending medicines, procedures, rehabilitation or other support.
Before leaving the appointment, clarify the next review date, who will communicate results, and whom to contact if the situation changes. Discuss difficulties with sleep, work, school, mobility, eating or emotional wellbeing when these are relevant. Practical support may require coordination between the treating clinician and other services.
The collected references do not establish a complete prevention or long-term outlook section for this entry. Missing information should not be interpreted as proof that prevention is impossible or that a particular outcome is inevitable. Ask what is known for the exact subtype, stage and personal circumstances, and which uncertainties remain.
When to seek emergency help
Severe breathing difficulty, collapse, new stroke-like symptoms, a seizure that is prolonged or repeated without recovery, uncontrolled major bleeding, or an immediate risk of self-harm require emergency help. In India, call 112 or reach the nearest emergency department. This is a general, non-exhaustive warning list; it is not a condition-specific triage tool.
Oncology is not listed separately on The Doctor Index; the nearest speciality is medical oncology. Every profile shows the doctor’s registration and what has been checked.
Sources
- Orphanet — Pineoblastoma — Orphadata Science, CC BY 4.0
- Human Phenotype Ontology Consortium — terminology definitions — HPO licence; definitions reproduced without alteration
- Government of India — Emergency Response Support System — Official reference for India emergency number
Source: MedlinePlus, National Library of Medicine. Orphadata Science: Free access data from Orphanet. © INSERM 1999; July 2026 data, CC BY 4.0. This product uses the Human Phenotype Ontology (hp/releases/2026-09-01). Only sources listed for this article apply. Source material has been selected and arranged; HPO definitions are reproduced without alteration. No source organisation endorses this compilation. Köhler S et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Research 2014;42(D1):D966–D974. doi:10.1093/nar/gkt1026.
General information, not advice about your situation. Errors can be reported through the corrections process. Reference TDI-C-1859.